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Abstract
Traumatic brain injury is a significant cause of death and disability and accounts for 16%
of injury-related emergency department visits in the United States. Current guidelines for
management of traumatic brain injury are focused on identifying and preventing
secondary brain injury using multimodal invasive monitoring techniques, including
cerebral oxygenation monitoring. However, these approaches have risks and there is
currently no clinical consensus that use of invasive monitoring improves patient
functional outcome. We will evaluate whether noninvasive monitoring of cerebral
oxygenation with near infrared spectroscopy can reduce the median duration of
brain tissue hypoxia in patients with severe traumatic brain injury. Specifically, we
will determine whether this method has benefit in combination with current guidelines,
versus management based on current guidelines alone. This study will provide evidence
that noninvasive cerebral oxygenation monitoring is a physiologic parameter that may
modify interventions to direct targeted treatments and improve outcomes in traumatic
brain injury.
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Chapter 1: Introduction
1.1 Overview
Traumatic brain injury (TBI) is a leading cause of death and disability among
people in the United States. In 2010, a report by the Centers for Disease Control (CDC)
estimated that of those diagnosed with a TBI, 87% (2,213,826) were treated and released
from the emergency department, 11% (282,630) were admitted and then discharged, and
2% (52,844) died.1 More than 3 million people in the United States are currently living
with long-term disability from secondary injury related to TBI, and self-report a higher
prevalence of activity limitation and reduction of life satisfaction, most notably in those
who had suffered a severe TBI.2,3 Severe TBI, defined as Glasgow Coma Scale (GCS) of
≤8, or motor score <5 if intubated, is associated with significant mortality and disability
among survivors due to prolonged hospital stays and sequelae of secondary brain
injury.4,5
Primary brain injury is defined as the direct mechanical forces that occur at the
time of traumatic impact to brain tissue and include traumatic shearing and tearing of
axons, diffuse axonal injury, and focal injuries such as intracranial hematomas.6,7 While
primary brain injuries occur seconds to minutes after trauma, they trigger a cascade of
secondary brain injury over time.8 Secondary brain injury may lead to the development of
decreased cerebral blood flow, cerebral hypoxia, intracranial hypertension, and cerebral
edema. It may also contribute to long-term complications, including seizures and the
development of epilepsy, dysautonomia and behavioral disturbances in the ensuing days
to months following the initial trauma.6,8,9
1.2 Multimodal Monitoring in Traumatic Brain Injury
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Modern management of TBI is centered on multimodal monitoring of
biochemical and physiological processes with the goal of identifying and preventing
secondary brain injury, which can improve functional and cognitive outcome and reduce
mortality.10,11 Although no single modality can recognize a detrimental physiologic event
with complete certainty, the simultaneous use of multiple monitoring techniques has been
accepted as an optimal strategy to guide treatments of TBI patients.10-13
When TBI occurs, intracranial hemorrhage or cerebral edema may cause a rise in
intracranial pressure (ICP). ICP depends on a fixed ratio of volumes within the skull:
brain parenchyma, cerebrospinal fluid (CSF), and blood. Based on the Monroe-Kellie
Doctrine, this intracranial volume is stable and an increase in one volume is offset by a
decrease in one or both of the remaining two.14 When compensatory mechanisms are
intact, this principle describes the ability of the brain to manage small increases in
volume without significant changes in ICP. However, when compensatory mechanisms
fail, even small increases in volume result in increased ICP, decreased cerebral perfusion
pressure (CPP), and reduced cerebral blood flow (CBF), which can compromise brain
tissue perfusion and lead to ischemia.11,15 Elevated ICP has been shown to be highly
predictive of mortality, and has been a focal point of monitoring and guiding TBI
treatment in the current literature.16,17 Therefore, ICP monitoring is currently
recommended by the Guidelines for the Management of Severe Traumatic Brain Injury in
all patients with a severe TBI and an abnormal computed tomography (CT) scan
revealing hematomas, contusions, swelling, or herniation.12,18
CPP is an important physiologic parameter that is often monitored simultaneously
with ICP in the management of TBI. CPP is the difference between mean arterial
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pressure (MAP) and ICP (CPP= MAP-ICP), and is therefore extrapolated from blood
pressure and ICP measurements. It represents the pressure gradient driving CBF, which
describes the extent to which oxygen and metabolites are being delivered to the brain
tissue.11,12 Optimizing CPP ensures adequate perfusion and prevents brain tissue hypoxia
(BTH) that may ultimately lead to ischemia.13 However, there is still uncertainty about
whether management should be focused on CPP, ICP, or both, and if directing
management towards one may be minimizing the importance of the other.13 Although a
multimodal monitoring approach has been widely adopted as the optimal strategy in TBI
care, there remains a lack of clinical consensus on specific monitoring modalities and
treatment protocols that are informed by those values.11
Table 1. Glasgow Coma Scale19
Category
Eye Opening

Best Verbal Response

Best Motor Response

Response
Opens spontaneously
Opens to verbal stimulus
Opens to painful stimulus
No eye opening
Oriented
Confused
Inappropriate
Incomprehensible
No verbal response
Obeys commands
Purposeful movement to painful stimulus
Withdraws from pain
Abnormal (spastic) flexion, decorticate posturing
Extensor (rigid) response, decerebrate posturing
No motor response

Score
4
3
2
1
5
4
3
2
1
6
5
4
3
2
1

1.3 Cerebral Oxygenation Monitoring
Cerebral oxygenation involves three main factors: CBF, arterial content of
oxygen, and cerebral oxygen consumption.13 In TBI, an imbalance between oxygen
delivery and consumption may ultimately lead to BTH.9 Increased incidence, duration,
3

and extent of BTH is associated with poor prognosis and functional outcomes; therefore,
a critical goal of multimodal monitoring is to ensure sufficient perfusion and oxygenation
of brain tissue.9 However, studies have shown that BTH is common in TBI and can occur
even in the presence of normal ICP and CPP.8,18 This highlights the importance of an
additional monitoring modality focused on cerebral oxygenation to supplement ICP and
CPP monitoring, and necessitates that care of TBI patients without cerebral oxygenation
incorporated into a multimodal monitoring approach is incomplete.6
1.4 Limitations of Cerebral Oxygenation Monitoring
Prior studies have suggested that the addition of invasive brain tissue oxygenation
(PbtO2) directed care in addition to the conventional ICP/CPP monitoring based
management may be associated with reduced burden of BTH.20-22 Some studies have
even suggested that management based on PbtO2 was associated with better short-term
outcomes and was a better indicator of long-term prognosis than ICP and CPP
management alone.23
However, obtaining PbtO2 requires an invasive monitoring technique that does
not come without limitations and risk.11 Although PbtO2 catheters can be placed through
a similar sized burr hole as an ICP monitor, they introduce post-surgical risk of infection
and bleeding, and there is a need for precise placement for accurate measurements.24
PbtO2 catheters only measure BTH regionally, and may provide vastly different data
based on the location and depth that the catheter is placed in the brain parenchyma.24,25
Placement on the more injured side of the brain may reflect the area most at risk for
secondary injury, but will not provide an accurate assessment of the cerebral oxygenation
in other areas. Alternatively, placement into a relatively healthy area of tissue may
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provide a falsely reassuring value that is not indicative of potential hypoxia in more
injured areas.24 Beyond its regional limitations, values are dependent on the patient’s
blood CO2 and O2 concentrations, temperature, and hypermetabolic states such as fever,
shivering and seizure activity.26-28 Therefore, a broader, noninvasive equivalent of
cerebral oxygenation monitoring would make a substantial contribution for those whom
invasive PbtO2 monitoring may be insufficient or introduce unnecessary risk.29
1.5 Near Infrared Spectroscopy
Near infrared spectroscopy (NIRS) is a noninvasive monitoring modality suitable
for continuous monitoring of surrogate changes in cerebral blood volume and cerebral
oxygenation.11,30 Although similar in technology to pulse oximetry, which measures
arterial oxygen saturation, NIRS measures tissue oxygen saturation, which consists of a
combination of measures from arterial, venous, and capillary blood.31 The principle
behind the technique is that infrared light is delivered via multiple emitters through the
scalp and into brain tissue noninvasively and can detect cerebral oxygenation and
measures of autoregulation on a global scale.32 Benefits of NIRS in the monitoring of
cerebral oxygenation include that is that it is noninvasive, does not require frequent
calibration, can be placed when an intracranial monitor may be unsafe, and minimizes the
challenge of a constant and precise location of probes.33
NIRS monitoring in TBI patients provides distinct advantages through its
noninvasive approach of detecting global rather than regional measures of cerebral
oxygenation, has resistance to motion artifacts, and is flexible in location and patient
positioning.34,35 In this way NIRS can be feasibly integrated into the clinical environment
to directly monitor total hemoglobin, deoxyhemoglobin, and oxyhemoglobin, which
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provides a parameter of cerebral oxygenation as well as a surrogate for measurement of
CBF.36
NIRS technology is applied using various devices which quantify cerebral tissue
oxygenation using equal (but device specific) indices such as tissue oxygen index (TOI),
as measured by the NIRO2 200NX, or the cerebral oxygenation saturation (SctO2), as
measured by CASMED-Foresight.37 Previous studies have shown that invasively
measured PbtO2 and noninvasively measured TOI respond to changes in arterial pressure
and ICP and that the direction of changes of TOI is concordant to that of PbtO2 in 77% of
the analyzed events.38 A study by Suzuki, et al. compared TOI to a blood gas analyzer
and showed excellent correlation between the two parameters, therefore validating its
efficacy in clinical use.39 Furthermore, a study by Al-Rawi, et al. defined a drop in TOI
(13%) based on NIRS that can be adopted as a threshold for identification of severe
cerebral ischemia with high sensitivity and specificity.32 These data demonstrate the
potential to identify NIRS derived thresholds for cerebral ischemia in the adult brain and
support the use of NIRS cerebral oxygenation monitoring in a clinical setting.32
1.6 Statement of the Problem
Use of ICP monitoring in severe TBI remains the gold standard in guiding
treatment, and there is a well-described relationship between mortality and elevated ICP
after TBI. However, there is still no large randomized clinical trial confirming its
effectiveness in guiding management, and to date there is no Level 1 clinical evidence
proving its mortality benefit. Additionally, ICP monitoring facilitates calculating the CPP
through the relationship that CPP= MAP-ICP. Similar to NIRS, ICP monitoring allows
for surrogate measures of cerebral perfusion. Optimal ICP or CPP thresholds have yet to
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be determined, and there is still debate over whether management of patients should be
targeted towards ICP or CPP as the main physiologic determinant.13,23 Once the primary
injury has occurred, therapy is directed towards preventing secondary brain injury by
ensuring the adequate delivery of oxygenated blood and nutrients to brain tissue to
minimize the risk of supply-demand mismatch. Prior studies have suggested that reduced
duration of BTH is associated with lower mortality rates, but authors acknowledge that
using PbtO2 as a monitoring technique has limitations. Monitoring with PbtO2 reflects a
regional rather than a global measure of cerebral oxygenation and requires an invasive
surgical procedure for placement of the catheter.12,18,40-42 NIRS as a noninvasive modality
of monitoring cerebral oxygenation has shown promise, but a larger randomized clinical
trial in TBI is necessary to provide definitive evidence of its benefit.10,29,43
Authors agree that the absence of sufficiently powered prospective studies and
clinical trials investigating the efficacy of these modalities has resulted in a lack of
clinical consensus in the monitoring algorithm of TBI. There has yet to be a functional
integration of all of these modalities that allow clinicians to make informed decisions
regarding management and intervention.10 Given the limitations of the current literature
and lack of definitive clinical data, further clinical trials are vital to establish optimal
methods and establish a standard of care among providers. Our proposed study will help
to clarify the clinical utility of noninvasive cerebral oxygenation monitoring as a
surrogate for cerebral perfusion in reducing BTH and whether its integration into the
multimodal monitoring approach is warranted to guide TBI treatment.
1.7 Goals and Objectives

7

Our proposed multicenter randomized controlled trial (RCT) aims to determine
whether cerebral oxygenation monitoring by NIRS can reduce the burden of BTH and be
incorporated into a standardized multimodal monitoring approach to guiding treatment of
severe TBI. The primary outcome will be to determine if treatment guided by cerebral
oxygenation monitoring with NIRS in addition to ICP monitoring can reduce the median
duration of BTH in the first 72 hours of injury as compared to ICP monitoring alone. This
outcome will determine the efficacy of NIRS as a monitoring modality in guiding clinical
decision making based on brain tissue oxygenation.
Our secondary outcome will be to determine functional outcome in each of our
groups at 6 months post initial injury utilizing the Glasgow Outcome Scale-Extended
(GOS-E) on an 8-point rating system. This information will determine whether the NIRS
based interventions improve functional outcome.
1.8 Hypothesis
We hypothesize that goal directed therapy based on brain tissue oxygenation
monitoring by NIRS plus ICP monitoring will show a difference in median duration of
brain tissue hypoxia over 72 hours, as compared to therapy guided by ICP monitoring
alone in the treatment of adults with severe traumatic brain injury.
1.9 Definitions
Median duration of BTH: median duration of time spent below threshold, defined as
SctO2 ≤ 50%, continuously measured and transmitted at 5 minute intervals over a 72
hour span.
Goal directed therapy: predetermined treatment protocol directed at a set combination of
physiological interventions that will address elevated ICP alone, or BTH and elevated
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ICP in conjunction, in treatment of TBI in each group. Specific protocol is defined in
section 3.5.1.
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Chapter 2: Review of the Literature
2.1 Introduction- Literature Search Criteria
A thorough review of the literature was conducted between July 2019 and April
2020 using Ovid Medline, Embase, Cochrane Medical Library and Pubmed. Only
English language articles were evaluated. Review of titles and abstracts determined
relevance to the proposed study for analysis. Key terms used independently or in
combination to search each database included: traumatic brain injury, severe traumatic
brain injury, monitoring, neurophysiological monitoring, intracranial pressure, cerebral
oxygenation, brain tissue oxygenation, near infrared spectroscopy, cerebral perfusion
pressure, autoregulation, brain tissue hypoxia, intracranial hypertension, Glasgow Coma
Scale, Glasgow Outcome Scale, Glasgow Outcome Scale Extended, IMPACT, CRASH,
functional outcome, and disability. Most clinical studies reviewed were observational in
nature, but a few influential RCTs were identified. Their analysis and review in relation
to our proposed study are detailed below.
2.2 Overview of Traumatic Brain Injury
TBI is caused by a blunt force, blast or penetrating wound that disrupts the normal
function of the brain.1 TBI has a range of short and long-term clinical outcomes including
cognitive and psychological impairments, functional disability, and death.1 Currently,
TBI severity is classified by the 15-point GCS based on a patients level of consciousness
and assessed by verbal, motor and eye opening response.2 Patients are then further
categorized into ranges from mild (GCS score 13-15), moderate (9-12) and severe (38).2,3 Recovery from TBI and return to baseline function is dependent on a complex
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pathophysiology that includes biochemical and cerebral metabolic disruptions, diffuse
axonal injury, hemorrhagic contusions, cerebral edema, and BTH, among others.3-5
In the prehospital and emergency room setting after TBI, the focus is on
resuscitating and supporting the primary brain injury, which is caused by the direct
mechanical forces of traumatic impact to brain tissue.2,4 Once a patient is transferred to
the intensive care unit (ICU), the effort shifts towards stabilization of hemodynamics and
systemic oxygenation to prevent secondary brain injury.4 Secondary brain injury can
result in irreversible damage if undetected; thus the goal is detecting it when there is still
time to intervene.6 Utilizing various physiological monitors, patient care is centered on
identification and management of secondary brain injuries that evolve in the hours to
days following the primary injury, which requires careful monitoring of cranial and
systemic physiology throughout their ICU stay.7-9
2.3 Review of Current Monitoring Strategies in Traumatic Brain Injury
Use of monitoring in TBI has been used for decades and is considered the basis
from which we guide our treatment. However, it is not the monitoring alone that affects
patient outcomes, but the ability to use that information to guide goal directed therapy.
There is no single monitoring modality that can guide management with complete
certainty, but use of a multimodal approach has been accepted as the optimal strategy in
maintaining cerebral physiology, improving functional outcomes, and reducing mortality
rates.6,10-12 It is widely believed that treatment informed by data from monitoring may
result in better outcomes than treatment informed solely by clinical assessment, as
patients with severe TBI are comatose. However, to date there have been no large RCTs
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confirming which monitoring modalities alone, or in combination, provide superior
guidance in directing therapy in TBI.10
2.3.1 Intracranial Pressure Monitoring
ICP monitoring has been the focal point of physiological monitoring in TBI care,
and is currently recommended by the Guidelines for the Management of Severe
Traumatic Brain Injury for all salvageable patients with a severe TBI and an abnormal
CT scan.10
In 2013, Alali, et al. conducted an observational retrospective cohort throughout
the United States and Canada from 2009-2011 that examined the relationship between
invasive ICP monitoring and in-hospital mortality. The study identified a large population
of patients with severe TBI who met the guidelines for ICP monitoring and compared
those who received ICP monitoring with those that did not.10 Data from more than 10,000
patients and 155 centers were utilized in determining that ICP monitoring was associated
with significantly lower odds of in-hospital mortality at the patient level (adjusted OR,
0.44; 95% confidence interval [CI] 0.31–0.63; p < 0.0001).13Although the large sample
size of this study provides external validity and is generalizable in the United States,
treatments based on monitoring were not controlled for, and details about those specific
protocols were not reported. Internal validity suffers due to the observational nature of
the study, and the authors admit to large variability of care among institutions at the
hospital level. This variability was thought to be due to treatment differences based on
clinical judgments of prognosis, which makes it more difficult to attribute success to ICP
monitoring guided treatment alone on a larger scale.10,13
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A 2013 prospective observational study by Talving, et al. studied a similar
population of 216 severe TBI patients who met the Brain Trauma Foundation’s (BTF)
criteria for ICP monitoring, and observed rates of in-hospital mortality and length of
stay.14 Their results supported Alali, et al. in their findings that ICP monitoring was an
independent predictor of overall in-hospital mortality, (adjusted OR 0.13 [95% CI 0.02–
0.81], p = 0.029) and showed a significant reduction in mean hospital length of stay by
-9.26 days (95% CI [-13.10 to -5.42], p <0.001). However, similarly to the study by Alali,
et al., the treatment protocol informed by ICP monitoring was not controlled for or
documented and was based on physician discretion, which introduces selection and
information bias. Additionally, the study’s external validity suffers due to the fact that it
was conducted at a single medical center.14
Additional retrospective cohort studies by Farahvar, et al. in 2012 and Gerber, et
al. in 2015 examined the relationship of ICP monitoring in TBI and 2-week in-hospital
mortality rates.15,16 Although both studies found a significant relationship to reduced 2week in-hospital mortality rates with ICP monitoring, there are concerns with both
designs. Farahvar, et al. identified their population retrospectively based on patients who
received ICP lowering treatments based on their clinical presentation, and then followed
their course from that point on to determine benefit.15 This design is problematic in that
they examined outcomes, but did not offer insight into how the monitoring itself, if
initiated at baseline, would guide treatment.15 Although the mortality rate for those
treated with an ICP monitor was 19.6% (n=212), compared with 33.2% (n=74) in those
treated without an ICP monitor, the question remains whether or not physicians decided
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not to monitor those patients whose condition was considered more severe and potentially
not salvageable, introducing bias.15
Although the findings were similar for Gerber, et al., their primary outcome was
mortality based on adherence to guidelines for ICP monitoring, which varied among
institutions and included guidelines for other factors. They studied severe TBI patients in
New York State from 2001-2009 and found that based on guideline adherence, 55.6% of
patients from 2001-2003 had ICP monitoring, which increased to 75.2% between 2007
and 2009 (p < 0.0001). There was also a significant association between mortality and
ICP monitoring compliance such that mortality in the noncompliance group was 25.8%
versus 18.6% in the compliance group (p=0.0002). However, it is difficult to establish
causality in this relationship due to the advances in other aspects of TBI monitoring and
care over that time period, and significant variability among patient demographics.16
Considering that ICP monitoring has been the standard of care in the BTF
guidelines for management of severe TBI, most evidence in support of ICP monitoring
has been observational in nature.10,13-16 A 2012 multicenter RCT by Chesnut, et al.
challenged this evidence by randomizing patients to protocols to treat intracranial
hypertension (ICH) (pathologically elevated ICP) based on either an invasive ICP
monitor or by clinical/radiological examination alone. 324 patients aged 13 or older in
Bolivia and Ecuador were randomized to receive either invasive ICP monitors or imaging
and clinical examination alone. Randomization was stratified according to study site, severity of injury, and age, and was conducted at 6 hospitals throughout Bolivia and
Ecuador that received a high volume of trauma patients. Their primary hypothesis was
that a management protocol based on ICP monitoring would result in reduced mortality
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and improved functional outcome as measured by GOS-E at 6 months compared to
management based on clinical/radiological evidence alone. Primary outcome was
survival and functional outcome as assessed by GOS-E at 6 months, and secondary
outcome was hospital length of stay.17
In contrast to findings by prior observational studies, the authors found that there
was no significant between-group difference in the functional and cognitive status based
on GOS-E (score of 56 in the ICP monitoring group vs. 53 in the imaging/clinical
examination group; p=0.49). Additionally, 6-month mortality was similar at 39% in the
ICP monitoring group and 41% in the imaging/clinical examination group (p=0.60), and
median length of stay in the ICU was similar in the two groups (12 days in the ICP
monitoring group and 9 days in the imaging/clinical examination group (p=0.25))17
As the only standardized, class 1 RCT providing evidence for ICP monitoring,
this study had excellent internal validity. The results were not significant to refute the use
of ICP monitoring and will not change the current recommended guidelines. However,
this contributes to the uncertainty of multimodal monitoring strategies in TBI care and
calls for additional research into a standardized algorithm of multimodal monitoring that
is proven beneficial to TBI management.
2.3.2 Cerebral Perfusion Pressure Monitoring
Over the past decade, emphasis has been placed on optimizing CPP in addition to
ICP in TBI. CPP is a surrogate for CBF and is the difference between systemic MAP and
ICP.10-12,18 CPP is directly influenced by ICP and MAP and can change based on
alterations in either physiologic variable. Ensuring CPP is adequate in an injured brain is
integral to maintaining sufficient blood flow and reducing secondary brain injury.
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Decreased MAP, elevated ICP, and the resulting decreased CBF can result in tissue
ischemia and infarction, supporting the importance of CPP in monitoring.19 However, the
question remains whether CPP monitoring alone, or in combination with other modalities
can provide the optimal guidelines for management of severe TBI.
The first assessment of CPP monitoring in the management of TBI was a 1990
prospective study by Rosner, et al. in 34 patients with severe TBI (defined here as GCS ≤
7). Their primary hypothesis was that CPP actively maintained between 70-80 mmHg
would improve mortality and outcomes based on the GOS. Their results showed a
mortality rate of 21%, and “good recovery rate” of 68%, based on their categorical scale
informed by GOS.20 Although the study had a small sample size and was conducted at a
single institution, it was the first study examining CPP as a physiological monitoring
parameter, established a reference range, and provided a necessary outline for
management protocols going forward.
A more recent retrospective cohort by Gerber, et al. in 2013 evaluated CPP
monitoring in severe TBI, whose findings were previously discussed in the analysis of
ICP monitoring. Not only did they analyze guideline adherence and mortality rates for
ICP monitoring, but for independent CPP monitoring as well. In New York State from
2001 to 2009, adherence to CPP treatment thresholds increased significantly from 14.6%
in 2001-2003 to 48.2% in 2009 (p<0.0001). CPP monitoring compliance was associated
with decreases in ICH (10.1% in the CPP noncompliance group in 2007-2009 versus
40.9% in 2007-2009 compliance group, p<0.0001). As mentioned previously, mortality
rates dropped significantly over this time period and correlated with significantly
increased adherence to CPP monitoring, as well as ICP monitoring.16
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These results suggest a role in CPP monitoring in the reduction of mortality in TBI
management. Not only did CPP monitoring adherence independently improve mortality
rates, but the fact that ICH improved when CPP was elevated indicates that ICP and CPP
monitoring together can contribute to mortality benefit. Strengths of the study include its
large sample size, multiple sites and duration. However, the study took place only in New
York, which reduces its generalizability to a larger population, and the authors admit that
variability among sites and patient demographics is significant. As discussed previously,
although there is a strong correlation with CPP monitoring and reduction of ICH and
mortality, it is difficult to prove causality.
A 2006 retrospective analysis by Huang, et al. studied 376 patients with severe
TBI over a 12-year period in Taiwan. Their main goal was to evaluate the efficacy of
management based on: a) ICP monitoring, b) CPP monitoring (CPP target >70 mmHg),
and c) CPP modified monitoring (mCPP) (CPP target >60 mmHg). Primary outcome was
functional status as assessed by GOS at 6 months, in which favorable was defined as
good recovery or moderate disability and unfavorable was defined as severe disability or
vegetative state. Among the sample, 77 were in the CPP targeted group and each group
was well balanced based on injury severity and demographics.
Results showed that mortality rates in the ICP only group were significantly
higher than in the CPP or mCPP groups (28.6% in ICP, 14.3% in CPP, and 13.5% in
mCPP, p=0.02 and p=0.03 respectively). In the CPP directed group, the percentage of
unfavorable outcomes was 22.1% and the percentage of favorable outcomes was 63.6%,
while in the ICP group the percentage of unfavorable outcomes was 22.7% and the
percentage of favorable outcomes was 48.8%. Not only was there a statistically
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significant reduction in mortality in both CPP groups versus the ICP group, but favorable
outcome in the ICP group was also significantly lower than in the CPP and mCPP groups
(p=0.04 and p=0.01, respectively). There was no significant difference between the two
CPP directed groups, but both showed significant benefit versus the ICP only group.21
These results suggest that a CPP targeted regimen is actually preferable over an ICP only
regimen in the guidance of treatment for TBI.
Although the results of Huang, et al. are initially convincing, the study lacks
internal validity due to its retrospective nature and lacks generalizability to the US
population. The authors also admit that poor outcomes in the ICP group may have been
attributed to poor clinical management strategies to lower ICP during this time period,
which have been modernized and improved in the time since. Ultimately, the question of
whether management should be directed towards CPP or ICP is still a matter of debate, as
directing management towards one parameter may be minimizing the importance of the
other.12
2.3.3 Brain Tissue Hypoxia
BTH is a common cause of secondary brain injury after severe TBI.22,23 Increased
BTH incidence, duration, and extent is associated with poor outcomes, and may result
even when ICP and CPP are maintained within targeted thresholds.22,24-26 Efforts to
maintain adequate cerebral oxygenation is therefore an important aspect of TBI
management and has been a topic recently addressed in the literature.
A systematic review conducted by Maloney-Wilensky, et al. in 2009 examined
three prior prospective observational studies that evaluated BTH and outcome based on
mortality and GOS scores at 6 months.27 Collectively, 71 out of 150 (47%) patients met
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the criteria for BTH, which was defined as brain tissue oxygen (BtO2) <10 mmHg
(measured regionally by a direct brain oxygen probe) and was standardized across all
three studies. Among those patients with BTH, 52 (73%) had an unfavorable outcome as
determined by GOS, and 39 (55%) died. In the absence of BTH, only 34 (43%) had
unfavorable outcome, and 17 patients died (22%). Overall, in patients who experienced
BTH (BtO2 <10 mmHg for >15 minutes), the odds ratio (OR) of unfavorable outcome
(death and disability) at 6 months was 4.00 (95% CI [1.9 – 8.2]), and the OR of death at 6
months was 4.6 (95% CI [2.2–9.6]), suggesting that BTH is significantly associated with
poor outcome after severe TBI.26,28,29
However, there are limitations to conclusions drawn from this data based on the
studies included. Considering that these studies were observational in nature, internal
validity suffers. The authors also admit that these studies may have been subject to bias
based on how risk factors for outcome were controlled. Additionally, differences in
where monitors were placed, when the GCS was recorded, or how frequently data were
obtained varied and may bias the results. But ultimately, the two major variables of
concern, outcome and GCS, were similar across studies and the findings are consistent
among the literature.27
2.3.4 Invasive Cerebral Oxygenation Monitoring
An attempt to establish a relationship between BTH, invasive cerebral
oxygenation monitoring and outcome was conducted in a 2009 retrospective cohort study
by Martini, et al. between 2004 and 2007. The study included 629 patients admitted with
diagnosis of severe TBI at a single Level 1 Trauma Center in Seattle, WA. Their primary
goal was to determine how clinical management based on PbtO2 monitoring affected
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mortality rates, neurological outcome (as measured by Functional Independence Measure
[FIM]), and resource utilization in this population. The entire population received ICP
monitoring, but 506 received ICP monitoring alone, while 123 received ICP monitoring
plus invasive cerebral oxygenation monitoring with PbtO2. The study found that there
was no observed reduction in hospital mortality rate with management guided by the
ICP/PbtO2 monitored group (29%) versus the ICP only group (23%). Even more
surprising is that in patients who survived, the likelihood of a good neurological outcome
(FIM≥ 7, which is defined as some level of independence) was actually smaller in the
ICP/PbtO2 monitored group (7.6 ± 3.0) versus 8.6 ± 2.8 in the ICP monitored group (p <
0.01). After adjustment, there was a significant, -0.75 (95% CI -1.41 to -0.09) point
reduction in mean FIM scores in patients with PbtO2 monitors versus ICP monitors
alone.30
Although this data seemingly contradicts earlier observations in the literature
regarding BTH and neurological and functional outcomes, there are significant flaws in
the study design and protocol that reduce its applicability. The observational nature of the
study and its single location had limitations on internal validity, and there was an
additional possibility that patients in the PbtO2/ICP group had a different initial
prognosis than those in the ICP group. In fact, patients in the ICP/PbtO2 group on
average were younger (35.7± 16.9 years) and had more severe brain injuries (GCS 5.1
±2.2) than in the ICP only group (40.7±19.6 years, GCS 5.6 ±2.3). The study reported
that as a result, patients in the PbtO2/ICP group received more aggressive management
and may have experienced serious adverse events. Finally, authors admit that the sample
size of each group was significantly different (n=506 in ICP monitoring group, n=123 in
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the ICP/PbtO2 monitoring group) and may have influenced results, and that the residual
confounding that was possible in their study warrants an RCT to better investigate the
relationship.30
In opposition to results concluded by Martini, et al., two retrospective analyses by
Oddo, et al. in 2011 and Narotam, et al. in 2009 found a significant reduction in BTH and
improved functional outcomes with management protocols guided by PbtO2.23,31 When
30-day outcomes were assessed, Oddo, et al. found that BTH (defined as PbtO2<15
mmHg) was longer in duration in patients with unfavorable outcomes (GOS 1-3,
8.3±15.19 hours) than in those with favorable outcomes (GOS 4-5, 1.7 ±3.7 hours,
p<0.01).23 When compared to an ICP plus CPP monitoring group, Narotam, et al. found
that management based on PbtO2 alone showed a significant reduction in BTH, mortality
rate and better long-term outcomes when evaluating GOS at 6 months. There was a 44%
improvement in mean BTH in the PbtO2 group (23.65 mmHg ± 14.40 mmHg) versus the
ICP/CPP group (16.21 mmHg ± 12.30; p < 0.001). Results also supported better
functional outcomes at 6 months in the PbtO2 group (GOS of 3.55 ± 1.75 versus 2.71 ±
1.65, p < 0.01; OR for good outcome 2.09, 95% CI [1.031- 4.24]). 31 Each of these
studies concluded that functional outcomes were better and mortality rates were lower
with decreased burden of BTH. Additionally, they reported that BTH was possible even
in the presence of normal ICP and CPP; and in the case of Oddo, et al., determined that a
management strategy based on PbtO2 alone was actually superior in preventing BTH
than in a protocol based on CPP and ICP in combination.23,31
In 2017, a two-arm, single blind, prospective randomized controlled multicenter
trial by Okonkwo, et al. (BOOST-II) evaluated the relationship of management guided by
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PbtO2 monitoring in severe TBI and functional outcome and mortality. Their main
hypothesis was that in patients with severe TBI, a management protocol informed by
PbtO2 and ICP values would reduce the total burden of BTH. 119 severe TBI patients
who met the BTF criteria for ICP monitoring were randomized to ICP monitoring only
(n=62) or ICP plus PbtO2 monitoring (n= 57), with patient demographics and injury
severity remaining similar among groups. Each patient enrolled, regardless of
randomization, was treated based on a tiered management protocol derived from the
Guidelines for the Management of Severe Traumatic Brain Injury and informed by values
indicated by their monitoring modalities.10
Results opposed Martini, et al. in that management for episodes of hypoxia based
on PbtO2 resulted in significantly less BTH (as measured by median proportion of time
below 20 mmHg) in the ICP+PbtO2 group (median .07) versus median .45 in the ICP
only group (p= 0.0000147). Additionally, 6-month GOS-E scores trended towards lower
mortality and better functional outcome in the ICP+ PbtO2 group with 25% mortality
versus 34% mortality in the ICP only group, although those results were not significant
due to limitations of sample size. At the 6-month evaluation checkpoint, 11% more
patients in the ICP+PbtO2 group achieved favorable outcomes (GOS-E of 5-8) than in
the ICP group, indicating improved recovery and return to functional status. In
conclusion, we can reasonably state that these results confirm the safety and feasibility of
a management protocol based on PbtO2 monitoring. BOOST-II also refutes Martini, et al.
and supports the hypothesis that PbtO2 directed therapy can mitigate secondary brain
injury by reducing BTH in severe TBI and can serve as a framework for future RCTs to
examine this association.
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Although the results of BOOST-II are convincing in their support of PbtO2 plus
ICP monitoring as an optimal strategy in guiding TBI management, there are still
limitations to the study design. Most significantly, the study did not recruit a sample size
sufficient to power results for clinical efficacy, but rather for a safety and feasibility
outcome. This was intentional by the authors, indicating that BOOST-II was a Phase II
trial confirming the safety and feasibility of their clinical protocol. Additionally, the
results trended towards lower mortality and better GOS-E scores at 6 months, but were
not significant due to limitations of sample size.25 Both of these flaws are the result of
being insufficiently powered, which can be addressed in a future RCT examining this
relationship. BOOST-III, which is now underway, will examine the impact of ICP
monitoring vs. ICP+PbtO2 monitoring on outcome in a study powered for clinical
efficacy.
2.3.5 Near Infrared Spectroscopy in Cerebral Oxygenation Monitoring
Cerebral NIRS measures cerebral oxygenation by indirectly measuring the
metabolic state of the brain tissue.6 It represents an exciting and novel approach to
noninvasive measurement of cerebral oxygenation across many spectrums, including
TBI.
Considering the current lack of clinical evidence for NIRS in adults with TBI,
correlation with existing modalities of cerebral oxygenation monitoring, such as PbtO2,
is necessary. In a 2012 retrospective analysis by Budohoski, et al., NIRS based
parameters of cerebral oxygenation were shown to have a significant temporal
relationship to PbtO2 and ICP. The goal of the study was to observe and categorize
cerebral oxygenation and perfusion in 42 TBI patients with PbtO2 and NIRS monitoring
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across a range of ICP and arterial blood pressures. The authors hypothesized that PbtO2
and NIRS could reliably monitor cerebral oxygenation but differed in their reaction times
to patterns of change in arterial pressure and ICP.
Results indicated that the direction of change of each modality was similar, but
NIRS reacted first to arterial pressure and ICP fluctuations, while PbtO2 showed a
delayed response. These results indicate that the modalities both reliably measure
changes in cerebral oxygenation but react on a different temporal scale. Among 25
occurrences of ICP fluctuation, there was a significant difference in latencies of detection
of events between PbtO2 and NIRS (p=0.04), but a consistent direction of change
between the two modalities. In arterial pressure fluctuations (96 events), there were
significant temporal differences between NIRS and PbtO2 detection (p<0.001), but again,
the majority in the same direction.
Overall, results indicate that with impaired cerebrovascular reactivity (ICP and
arterial pressure fluctuations), NIRS parameters and PbtO2 were concordant in 77% of
events.32 However, the retrospective and observational nature of the study limits its
internal validity. Although there is significant correlation between arterial pressure, ICP
and cerebral oxygenation (measured by NIRS and PbtO2), it does not provide proof of
causality. These results are important in establishing the relationship between PbtO2 and
NIRS and provide evidence that NIRS can be utilized in cerebral oxygenation monitoring
in TBI similarly to the way PbtO2 has been in previous trials, but the need for a large
RCT establishing this relationship is clear.
In addition to cerebral oxygenation, NIRS can be used as a noninvasive method
for continuous detection of cerebral blood volume as a marker of cerebral autoregulation.
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Cerebrovascular pressure reactivity (PRx) is the capability of cerebrovascular smooth
muscle to react to changes in transmural pressure. Autoregulation is the maintenance of
cerebral blood flow over a wide range of arterial blood pressure, based on changes in
resistance to cerebral vasculature.10 PRx, therefore, is the index by which autoregulation
can be measured, and is calculated using CPP (MAP-ICP), which requires invasive ICP
monitoring and continuous assessment of arterial blood pressure. Alternatively, using a
noninvasive NIRS based index of cerebrovascular reactivity called total hemoglobin
reactivity (THx), one study hypothesized that continuous recording would correlate with
PRx and provide similar information about optimal arterial blood pressure and CPP in
ensuring adequate autoregulatory status in TBI.
In this prospective observational study by Zweifel, et al., 40 patients with TBI
were recorded 120 times daily using either NIRS to determine THx or invasive ICP
monitoring to derive PRx. Authors found a significant correlation between PRx and THx
indices (r=0.49, p<0.0001) across averaged individual recordings, which increased to
r=0.65, p<0.0001 when patients with possible confounding factors were excluded.33
These results indicate that NIRS derived indices of autoregulation (THx) can be used as a
noninvasive alternative to determine optimal CPP and MAP in TBI patients. Although
significant, data was obtained from a single site with limited sample size, which limits
external validity. In their review, Davies, et al. mentioned that only events where changes
in ICP resulted in a significant change in THx were considered for analysis. It is possible
then that there were significant events of elevations in ICP that evoked no change in
NIRS parameters.34 Additionally, correlation increased between the two techniques when
patients with frontal contusions were excluded, indicating the possibility that superficial
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contusions or hematomas on the scalp may interfere with NIRS signal acquisition, a
major limitation in TBI patients. However, this method may be particularly beneficial in
patients whom invasive monitoring is contraindicated, unavailable or poses unacceptable
risk. This study adds clinical significance to the utility of NIRS for measurement of
autoregulation in addition to cerebral oxygenation.
A 2015 Phase II RCT by Hyttel-Sorensen, et al. evaluated the influence of NIRS
monitoring on treatment guidelines in 166 preterm infants. Their primary hypothesis was
that the burden of BTH could be reduced by a treatment guideline informed by cerebral
NIRS monitoring.35 During the first 72 hours of life, infants were randomized to cerebral
oxygenation monitoring with NIRS (n=86) or blinded monitoring (n=80), in which their
treatment would be dependent upon. Their primary outcome measure was BTH as
measured by time spent outside of a defined target cerebral oxygen range and expressed
in percent hours; and secondary outcome was defined as all-cause mortality.
Results concluded that the 86 infants randomized to NIRS monitoring had a
significantly reduced median duration of BTH (16.6% hours [IQR 5.4-68.1%]) compared
to the blinded group (53.6% hours [IQR 17.4-171.3]; p=0.0012), and a trend towards
reduced all-cause mortality, although results were not significant. These results indicate
that NIRS cerebral oxygenation monitoring can be successfully utilized to guide a
treatment protocol to significantly reduce burden of BTH without the risk of serious
adverse events.35
A major limitation of this study was clearly the population of interest and lack of
generalizability, in that these patients were premature infants and did not suffer a TBI.
The authors also admit that there was variability in the delivery of treatment protocols
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due to inconsistent clinical discretion of the healthcare team among different sites, and
that complete blinding of group allocation to the staff was not possible. Although there
are limitations to the study, this was the first multicenter RCT in analysis of NIRS in a
human population and showed promising results in its applicability for clinical use.
While results indicate that this technology can be successfully utilized in human patients,
a review by Davies, et al. pointed out that cerebral NIRS is a more established modality
in neonatal intensive care due to favorable anatomical factors in the population such as
decreased skull thickness.34,36 Reflecting the opinions of other authors, Davies, et al. call
for large cohort prospective clinical trials to demonstrate the optimal use and clinical
efficacy of NIRS monitoring in the adult TBI population.
2.4 Review of Prognostic Indicators
In order to predict the risk of unfavorable outcomes or death in patients with
severe TBI, baseline prognostic models have been created that correlate significantly with
6-month GOS-E scores. The International Mission on Prognosis and Analysis of Clinical
Trials (IMPACT) study gathered data from 9,205 patients with moderate and severe TBI
(defined as GCS ≤12) from eight RCTs and three observational studies between 1984 and
1997.37 Prognostic scoring algorithms were then derived from the IMPACT study by
Steyerberg, et al., and were found to have individual statistical significance in correlating
to GOS-E 6-month outcome scores. The baseline characteristics used in calculating
prognosis are obtained at initial presentation, which allows for application of the model
before in-hospital therapeutic interventions.38 Baseline characteristics in the IMPACT
prognostic lab model include: demographics (age, sex, race), indicators of clinical
severity (cause of injury, GCS components, pupillary reactivity), secondary insults
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(hypoxia, hypotension, hypothermia), blood pressure, Marshall CT classification,39
presence of intracranial hematomas, glucose, and hemoglobin at time of admission.38 The
IMPACT core model is an abbreviated adaptation of the lab model that is composed of
age, GCS motor score, and pupillary reactivity and has been utilized in studies such as
BOOST-II to control for prognostic indicators of clinical severity between control and
intervention groups.25,38
Table 2. IMPACT Core Model Prognostic Indicator37,38
Characteristics
Age (years)

Motor Score

Pupillary reactivity

Value
≤ 30
30-39
40-49
50-59
60-69
70+
None/extension
Abnormal flexion
Normal flexion
Localizes/obeys commands
Untestable/missing
Both pupils reactive
One pupil reactive
No pupil reactive

Score
0
1
2
3
4
5
6
4
2
0
3
0
2
4

Sum Score Core Model
A 2012 external validation study by Roozenbeek, et al. confirmed that the
IMPACT prognostic model was generalizable and can be reasonably applicable to
classify TBI patient populations based on prognostic risk, which may be ultimately
indicative of GOS-E outcome scores.40 In our proposed study, IMPACT core model
scores will be obtained and matched between groups in order to reduce the imbalance of
important prognostic indicators, and then compared to GOS-E outcome at the completion
of the trial.
2.5 Review of Relevant Methodology
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This section will briefly review relevant methodology of the studies reviewed
above to further validate our proposed study design and designation of methods.
2.5.1 Review of Studies to Identify Possible Confounding Variables
Most studies that investigate the clinical utility of monitoring modalities in TBI
care employ observational studies to obtain their data. This type of study design is
appropriate when there is a standard of care, such as ICP monitoring, which is being
investigated or modified.10 Most studies included in review, despite a select few seminal
RCTs, have utilized observational studies to make conclusions about their hypothesized
associations. Although almost all studies reach statistical significance in some outcome,
potential confounding variables to their study designs will be reviewed.
Large retrospective observational cohorts are beneficial in analyzing a large
sample with high external validity but are susceptible to confounding by uncontrolled
variables. Several confounders were controlled for consistently among reviewed studies
to reduce this effect, including gender, race, comorbid illnesses, injury mechanism and
severity, type of intracranial lesion, and vital signs (including GCS) in the emergency
department and during hospital stay. But authors admit that physician judgment, the
course of the patient during the hospital stay, and the lack of availability of trained staff
were all possible confounders that they could not reasonably control in this type of study
design.13 A widespread issue among observational studies included in review is the
inability to control for physician biases or preferences, in that they may decide to place a
particular monitor or not in patients because of an anticipated favorable or unfavorable
outcome.13-16 As Farahvar, et al. explain, to determine why some patients were treated or
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not, and the decision behind it, is beyond the scope of their study and is a topic requiring
investigation.15
A prospective, observational study by Talving, et al. attempted to reduce bias
from confounding factors by utilizing propensity matching; a technique that tries to
estimate the effect of a treatment by accounting for the covariates that predict receiving
the treatment.14 This technique specifically addressed the issue of physician bias in the
decision to treat, or not. Regardless, a major issue in an observational design is that even
when the decision is made to place a monitor or not, treatment regimens were largely
dependent on clinical judgment. Physician discretion ultimately determined treatment
plans, and it was possible that patients with ICP monitors were treated more aggressively
than those without.14 In fact, the retrospective cohort by Martini, et al. did collect
information on patient demographics in each arm of their study (ICP monitoring alone
versus ICP plus PbtO2 monitoring), and found that there was bias in decision to treat.
Patients in the intervention group (ICP plus PbtO2 monitoring) on average were younger
and had more severe brain injuries than in the control group (ICP monitoring only), and
consequently received more aggressive management.30 The opposite was observed in a
single site retrospective analysis by Budohoski, et al., where treatment protocols were
well established but patient characteristics varied. Although the treatment protocol was
controlled for, sample size was small, and patient characteristics were significantly
different (including injury type and severity based on GCS). Similarly to a study by
Oddo, et al., the authors admit that confounding was possible based on the variable
placement/location of devices, and the variable duration of monitoring among
patients.23,32 It is clear from the studies reviewed that management of severe TBI is
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complex and multifaceted, and RCTs are necessary to control for patient demographics,
monitoring protocols, and treatment algorithms within each study design.
In a review of RCTs, efforts were made to reduce confounding by creating
guidelines for randomization and an established treatment protocol based on each
treatment arm.17,25,35 Despite this, a RCT by Hyttel-Sorensen, et al. still found that
implementing treatment protocols based on NIRS monitoring was complex and difficult
to apply across their entire sample size.35 A tiered management protocol guided by PbtO2
and ICP monitoring was largely successful in BOOST-II; although they admit that
treatment aimed at improving cerebral oxygenation had a small risk of significant adverse
events, specifically respiratory events (4%), which may have confounded 6-month
outcome measures.25 In conclusion, the RCT design allows for implementation of
specific interventions, treatment guidelines, elimination of physician bias, and minimizes
the effects of inter-subject variability, and is a logical choice for our proposed study.
2.5.2 Study Design
As previously discussed, authors collectively agree that a large prospective RCT
is necessary to establish the significance and clinical efficacy of a multimodal monitoring
approach in TBI. Successive editions of the Guidelines for the Management of Severe
Traumatic Brain Injury have noted that data from RCTs that have been conducted is
lacking, and only a few high quality prospective cohort studies exist.10 In our proposed
two-arm single blind prospective, multicenter RCT, we will be able to control for
confounding, reduce physician bias, and obtain high quality evidence to establish a
relationship between a treatment protocol informed by cerebral oxygenation monitoring
by NIRS and its effect on BTH and functional outcome.
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2.5.3 Study Population and Selection Criteria
In accordance with the Guidelines for the Management of Severe Traumatic Brain
Injury, observational studies, and adaptations from RCTs by Okonkwo, et al. and
Chesnut, et al., the population selected will meet certain characteristics.10,15-17,23,25
Patients will be 18 or older with severe TBI and meet clinical need for ICP monitoring.
Selection will come from three academic, tertiary care, level I Trauma centers in the state
of Connecticut with the appropriate resources to monitor and treat to the specifications of
our protocol. Inclusion of three of the largest and most diverse medical centers in the
state will allow for appropriate external validity. Like other studies in review, inclusion
criteria will consist of severe TBI as defined by admission GCS and baseline
demographic characteristics. Exclusion criteria will be similar to conditions established
by previously reviewed studies, and include penetrating injury, GCS out of specified
range, pregnancy, and age out of specified range, among others. Specific inclusion and
exclusion criteria will be discussed in detail in Chapter 3.
2.5.4 Selection of Variables
Our proposed intervention will be cerebral oxygenation monitoring by NIRS plus
ICP monitoring for 72 hours to guide a specified treatment regimen to determine efficacy
of reducing burden of BTH and improving 6-month functional outcomes. Monitors will
be placed within 12 hours of admission after confirming eligibility criteria based on
inclusion and exclusion guidelines and consent agreement. Our proposed study design,
timing and duration of monitor placement is comparative to previous RCTs that had
analyzed the relationship of multimodal monitoring in TBI.17,25 Although the trial by
Chesnut, et al. found no significant improvement in functional outcomes with ICP
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monitoring, its inability to refute its efficacy and the inclusion of ICP monitoring in the
current guidelines is the primary factor for inclusion in our study as our control.10,17
Additionally, safety and feasibility of regional brain tissue oxygen (PbtO2) monitoring
was supported in BOOST-II, but was underpowered to show clinical significance, though
there was a trend towards improved outcomes.25 Well-documented limitations in PbtO2
monitoring, insufficient data, and promise for noninvasive strategies such as NIRS
cerebral oxygenation monitoring is the primary determinant for including NIRS
monitoring in our intervention arm instead of PbtO2.12,25,35
2.5.5 Treatment Protocol
The primary variable in our study design is the monitoring modality that each
patient is randomized to; either NIRS plus ICP monitoring, or ICP monitoring alone, and
how that approach influences treatment. Based on those physiological parameters and the
treatment they guide, we will determine the efficacy of cerebral oxygenation monitoring
by NIRS and ICP monitoring in reducing BTH and improving long-term functional
outcome. A stepwise management protocol will be standardized across our study and
adapted from the Guidelines for the Management of Severe Traumatic Brain Injury and
BOOST-II.10,25 A protocol based on ICP values and cerebral oxygenation values by
PbtO2 was safely and feasibly implemented in BOOST-II.25 We will use a similar
protocol and adapt its thresholds based on NIRS criteria for BTH, instead of PbtO2,
which will be described in greater detail in Chapter 3.
2.5.6 Primary and Secondary Outcomes
Our primary outcome is to determine if treatment guided by cerebral oxygenation
monitoring with NIRS in addition to ICP monitoring can reduce the burden of BTH over
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72 hours as compared to ICP monitoring alone. As previously discussed, BTH is a
common cause of secondary brain injury after severe TBI and its extent, duration and
depth is associated with negative outcomes in this population.22,24-26 BTH has been
analyzed as an outcome measure in a number of previously reviewed studies, and
therefore it is reasonable to propose that median duration of BTH over both arms will be
the primary measurement by which efficacy of both the intervention and control groups is
determined in our study.23,25,35
Our secondary outcome is to determine the functional outcome in each of our
groups at 6 months post initial injury utilizing the GOS-E 8-point rating system. Almost
all of the studies reviewed utilize some measurement of outcome, whether it be inhospital mortality,13-16,30 overall mortality,17,31,35 GOS,23,31 or GOS-E.17,25 GOS-E is an
expanded 8-point ordinal outcome scale and provides increased sensitivity relative to the
original 4-point GOS that was used in earlier studies. Using GOS-E allows for
classification of a wider range of functional outcomes including death, and corresponds
to a necessary sample size reduction on the order of 3-5%.41 Additional outcomes will
include number of interventions taken in each group, and incidence of serious adverse
events throughout the entire study period.
2.5.7 Conclusion
The existing evidence supports the promise of cerebral oxygenation monitoring in
guiding treatment regimens to lower BTH and improve functional outcomes in severe
TBI. Clarifying its use in clinical practice alongside the current accepted standard of
multimodal monitoring is essential to inform its efficacy and utility in treatment of this
population. Exploring the possibility of monitoring cerebral oxygenation in a noninvasive
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manner through NIRS is an exciting advancement in the field that has been shown to
have preliminary success and is a logical choice for further investigation. Authors
recognize that there are still inconsistent outcome measures, confounding, and
inconclusive data regarding the utility and use of certain monitoring modalities in TBI
care. Our proposed multicenter RCT will allow for control of confounding factors, a
standardized outcome measure consistent with recent literature, and determination of
clinical efficacy of multimodal monitoring in TBI.
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Chapter 3: Study Methods
3.1 Study Design
We will conduct a two-arm single blind prospective, multi-center RCT among
adult hospitalized patients with severe TBI. We will compare the median time of BTH in
TBI with patients being managed with a treatment protocol informed by ICP monitoring
alone (control) against one informed by ICP monitoring plus cerebral oxygenation
monitoring with NIRS (intervention).
3.2 Study Population and Sampling
Our source population will be derived from inpatient adults aged 18 and older
with severe TBI and clinical need for ICP monitoring according to the Guidelines for the
Management of Severe Traumatic Brain Injury, 4th Edition.1 Eligible medical facilities
include three academic, tertiary care, Level 1 trauma centers in the state of Connecticut:
Yale New Haven Hospital, St. Francis Hospital and Hartford Hospital.
Inclusion criteria will consist of the following: male and female patients aged 18
and older admitted to eligible medical centers with severe TBI, not following commands
after resuscitation and without influence of paralytics or sedation, clinical need for ICP
monitoring according to the Guidelines for the Management of Severe TBI, 4th edition,
and ICP monitor placement within 12 hours of presentation.
Exclusion criteria will include: penetrating brain injury, neurological exam
suggestive of imminent brain death, uncertain neurologic exam, pregnancy, chest/lung
injury evident on diagnostic imaging likely to produce hypoxia independent of brain
injury, and inability to obtain authorized consent from subject or from legal authorized
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representative (LAR). Presence of intracranial hematomas will not be excluded, and will
be reported in participant baseline characteristics (Table 3).
3.3 Subject Protection and Confidentiality
This study will be reviewed by the Institutional Review Board (IRB), a
commission of Yale University’s Human Research Protection Program, in accordance
with IRB Policy 100 PR.1. Based on the functional and cognitive status of our study
population, we will act in accordance to IRB Policy 340: Participation of Individuals with
Impaired Consent Capacity, which will employ additional safeguards in order to protect
our participant’s rights and welfare, including appropriateness and justification of
inclusion, risk/benefit assessment, and the use of a surrogate or LAR for decision making
on each subject’s behalf. We will require written, informed consent (Appendix B) from
each LAR before inclusion, which will outline the purpose of the research, study design
and procedures, expected duration, risks, and potential scientific and personal benefit of
their participation. In addition, the consent form will outline that each LAR has the right
to withdraw from the study at any time if he/she feels unsatisfied with treatment.
Continued participation consent will be obtained at or before the 6-month follow-up visit
by LAR or participant if they regain cognitive capacity. All clinical information in this
study will be kept confidential and research will be conducted in accordance to the Health
Insurance Portability and Accountability Act (HIPAA). Additionally, all clinical and/or
research staff involved in care of participants will be required to undergo HIPAA training
prior to initiation of this study if they have not already done so.
3.4 Recruitment
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Any patient over the age of 18 who presents to the emergency department of
participating locations with mechanism of injury consistent with head trauma will be
evaluated in conjunction with the trauma surgery/ neurocritical care team for inclusion
criteria. Once a thorough trauma assessment has been completed, the patient is
hemodynamically stable and diagnostic imaging is complete, they will be evaluated for
inclusion criteria. If the patient is deemed a viable candidate, an LAR will be identified
and given information and consent to enroll in the study. Since this protocol is time
sensitive, it is imperative that an LAR is identified in a timely fashion, and that study
guidelines, eligibility, and medical and scientific benefits of their enrollment are
discussed before agreement.
3.5 Study Variables and Measures
The intervention group will include patients managed by a protocol determined by
ICP and cerebral oxygenation monitoring with NIRS, while the control group will be
patients managed by a protocol determined by ICP monitoring alone. Intraparenchymal
ICP monitors and noninvasive NIRS monitors will be placed within 12 hours in each
patient before they are subsequently randomized. In the intervention group,
measurements of ICP, SctO2 (as measured by NIRS) and CPP will be monitored at 5minute intervals, and treatment will be initiated in a stepwise fashion based on specific
physiological thresholds. In the control group, the same protocol will be in place, but
providers will be blinded to SctO2 and instructed to manage based on ICP and CPP
alone.
The primary outcome will be to determine if treatment guided by cerebral
oxygenation monitoring with NIRS plus ICP monitoring can reduce the burden of BTH
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over a 72-hour period as compared to ICP monitoring alone. The secondary outcome will
be functional outcome as defined by GOS-E at 6 months post initial injury, evaluated by
a trained member of our research team who was blinded to the intervention group.2 An
additional secondary outcome will be number of interventions taken in each group.
3.5.1 Treatment Algorithm and Thresholds
Treatment protocols and thresholds will be adapted from the current Guidelines
for the Management of Severe Traumatic Brain Injury, 4th Edition, as well as BOOST-II.
Treatment protocol is directed at a set combination of physiological interventions that
will address elevated ICP alone, or BTH and elevated ICP in conjunction. Our control
and intervention groups will be managed based on specific thresholds for intervention,
which include: ICP ≥ 22 mmHg; CPP ≤ 60 and ≥80 mmHg; unintentional hyperthermia
or hypothermia; blood glucose <60 or >150 mg/dL; and standard hospital protocol
involving correction of electrolyte abnormalities. The intervention group will be managed
with the addition of a physiological threshold of BTH, defined as: SctO2 (as measured by
NIRS) ≤ 50%. With utilization of medical management defined by these thresholds, the
median duration of BTH over a 72-hour period will be determined among each group.
After initial stabilization, standard management will include early identification
and evacuation of all traumatic hematomas and intubation and ventilation with goal of
SaO2 > 93% and PaCO2 30-40 mmHg. Increase in PaCO2 is associated with an increase
in cerebral blood flow, which in turn provides increased oxygenation to brain tissue, but
may increase total brain volume and ICP as well.1 Subsequent treatment protocols will be
grouped based on which physiologic threshold is breached. The control group will trigger
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intervention only with evidence of ICH, while our intervention group will trigger
intervention if either variable is out of range.
1) Group A: ICP < 22mmHg, SctO2 > 50%, no treatment required.
2) Group B: ICP ≥ 22, SctO2 > 50%, will require treatment in both control and
intervention group based on the presence of elevated ICP.
3) Group C: ICP < 22mmHg, SctO2 ≤ 50%, will require treatment from the intervention
group based on BTH, but will not require treatment in the control group based on ICP
within defined range.
4) Group D: ICP ≥ 22, SctO2 ≤ 50%, will require treatment from both the control and
intervention groups, based on the presence of elevated ICP and BTH.
Brief physiologic elevations in ICP or reductions in SctO2 may occur throughout
the 72-hour monitoring period, so our threshold to intervene will occur at 10 minutes (or
two consecutive readings, measured 5 minutes apart) of continuous elevated ICP or BTH
as defined by our values above. The following protocol will outline the specific
interventions that will be taken to correct the variance in either ICP or SctO2, and will be
taken in a stepwise approach as listed. If at any point during the protocol physiological
variables return to normal range, clinicians should discontinue further intervention.
Group B Intervention: (1) elevate head of bed, (2) ensure sufficient sedation of the
patient with propofol at 0.3 mg/kg/hour, titrating by 5 to 10 mcg/kg/minute every 5 to 10
minutes until proper sedation is achieved,3 (3) ensure T <38° C, control with IV
acetaminophen as needed, as fever increases metabolic demand and can increase ICP
with elevated CBF, (4) transfuse 1 U pRBCs until Hgb ≥ 7 mg/dL, (5) hypertonic saline
250 mL IV bolus titrated to control ICP, while maintaining serum Na+ 155-160 mEq/L,
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(6) IV Mannitol 1g/kg 20% solution, with repeat dosing every 6-8 hours as needed at
0.25-1 g/kg and maintaining systolic BP > 90 mmHg, (7) therapeutically adjust
ventilatory rate to lower PaCO2 to 32-35 mmHg. If refractory, (8) repeat CT Head noncontrast to evaluate for bleeding or mass effect, then (9) consider removal of CSF at 1-2
mL/min with external ventricular drain (EVD) into the lateral ventricle on least affected
side, (10) pentobarbital bolus at 5-20 mg/kg, titrated at 1-4 mg/kg/hour to achieve
induced coma, and finally (11) decompressive craniectomy.
Group C Intervention: (1) elevate head of bed, (2) ensure T <38° C, control with IV
acetaminophen as needed, (3) transfuse 1 U pRBCs until Hgb ≥ 7 mg/dL, (4) increase
PaO2 by adjusting ventilator parameters to increase FiO2 to 60% initially, increase until
100% as needed based on response, (5) increase PaO2 by increasing Positive End
Expiratory Pressure (PEEP) accordingly, (6) therapeutic hyperventilation to increase
PaCO2 to 45-50 mmHg, (7) transfuse pRBC to goal Hgb > 10 g/dL.
Group D Intervention: (1) elevate head of bed, (2) ensure T <38° C, control with IV
acetaminophen as needed, (3) pharmacologic sedation as listed in Group B protocol
above, titrated to effect, (4) transfuse pRBCs until Hgb ≥ 7 mg/dL, (5) hypertonic saline
250 mL IV bolus titrated to control ICP, while maintaining serum Na+ 155-160 mEq/L,
(6) IV Mannitol 1g/kg 20% solution, with repeat dosing every 6-8 hours as needed at
0.25-1 g/kg and maintaining systolic BP > 90 mmHg, (7) obtain arterial blood gas to
determine if oxygenation is within desired range, if not, increase FiO2 by increasing
PEEP accordingly (increase to 60% and up to 100% as needed based on response), (8)
remove CSF at 1-2 mL/min with EVD as listed in Group B protocol. If treatments are
refractory, consider (9) high dose IV Mannitol >1 g/kg 20% solution, (10) transfuse
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pRBCs until Hgb ≥ 10 mg/dL, (11) attempt to increase CPP >70 mmHg with IV normal
saline fluid boluses, (12) repeat CT Head non-contrast to evaluate for bleeding or mass
effect and then (13) treat surgically correctable lesions with craniotomy, (14) induced
hypothermia to 35-37° C using active cooling measures, (15) pentobarbital bolus at 5-20
mg/kg, titrated at 1-4 mg/kg/hour to achieve induced coma, (16) induced hypothermia to
32-34.5° C, and finally (17) decompressive craniectomy.
3.6 Assignment of Intervention and Blinding
Participants who meet inclusion criteria will be randomly allocated by computer
generation to either intervention or control group in a matched, one to one ratio until
sample size in each arm is achieved. To reduce the likelihood of an imbalance of clinical
severity factors between groups, a covariate-adjusted randomization scheme will be used
in this study.4 The goal of randomization is to create groups that are comparable with
respect to prognosis and clinical site and without selection bias. Therefore, adjustment
variables will include two factors: clinical site, and probability of a poor outcome as
defined by the IMPACT core model. Matching based on prognosis will occur by
separating subjects into three distinct categories as determined by IMPACT core model
scores and distributed evenly among both control and intervention groups. Categories
will be defined as: (a) IMPACT score 0-5, (b) IMPACT score 6-10, or (c) IMPACT score
11-15. Subjects will then be evenly distributed among these three categories and the three
included clinical sites. This scheme will be utilized to prevent an imbalance of participant
inclusion from any one particular site, and clinical severity imbalances among groups.
Otherwise, as long as participants meet inclusion criteria no preference to either group
will be given based on mechanism of injury, comorbidities, gender, or physician
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determined prognosis of outcome. Therefore, nonbiased representation of each group will
be maintained throughout our study.
Researchers involved in our study including those collecting data, any
nonessential healthcare providers, and researchers evaluating GOS-E will be blinded to
allocation group. Based on the nature of our study design, it is impossible to blind
individual healthcare providers responsible for implementing treatment protocols once
each monitor is in place. However, treatment protocols have been controlled for, which
will eliminate physician biases and limit potential confounding. Additionally, LAR’s and
family members will be blinded to group assignment and treatment protocol, as will be
outlined in their consent agreement.
Table 3. Participant Baseline Characteristics
Characteristic
Subjects (n)
Average Age
Male Gender (%)
Race (%)
- White
- Black
- Hispanic
- Other
Average GCS (3-15)
Average Motor Score (0-6)
Average IMPACT score (0-15)
Evidence of Hematoma on CT (%)
- Epidural Hematoma (%)
- Subdural Hematoma (%)
- Subarachnoid Hemorrhage (%)

Control

Intervention

P-Value

-

-

-

3.7 Adherence and Monitoring of Adverse Outcomes
In order to reduce drop out rates after our initial outcome is assessed, recruiters
from the research study will be contacting subjects and LAR’s once a month via
telephone or electronic mail in order to maintain communication before their scheduled
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6-month follow-up. They will be contacted again one week before their scheduled
follow-up appointment to ensure their participation and coordinate logistics of their
appointment. Participants will be reimbursed for any travel expenses pertaining to inperson follow-up at their 6-month appointment.
During communication, participants will be asked to provide information on
serious adverse events (SAE), which will be defined in our study as any medical
occurrence that results in death, is life-threatening, requires inpatient hospitalization or
prolongation of existing hospitalization, or results in persistent or significant disability or
incapacity.5
3.8 Data Collection
Once an LAR has signed consent and the subject is hemodynamically stable, an
ICP monitor will be inserted 1.5-2 cm into brain parenchyma through a burr hole, with
positioning close to, but not directly in the area most at risk. Subjects will then undergo a
non-contrast CT Head to evaluate for proper placement of each monitor. CASMEDForesight NIRS monitors will subsequently be placed and each respective modality will
record ICP and SctO2 continuously. These values will be transmitted at 5-minute
intervals over the 72-hour span and sent to a private laptop for data compilation that will
be analyzed at the completion of each individual trial. Attending clinical staff will also be
responsible for routine monitoring and charting of significant events, repositioning, vital
signs, routine lab work, ventilator settings and arterial blood gas values when available
(pH, PaCO2, and PaO2).
As described in section 3.7, research staff will maintain communication with
subjects and LARs at specified intervals after the initial 72-hour monitoring period is
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complete. Six months after initial presentation each subject will be evaluated by a trained
researcher for functional status as outlined by GOS-E. Evaluation will be done at a
private site in New Haven, CT by a single evaluator, and coordination of logistics will be
done previously to ensure each subjects attendance. If a subject is in the hospital or
rehabilitation facility at the time of their session and is not safe to leave, additional
measures will be taken so that the evaluator can conduct the evaluation at their current
location. Each session will consist of a standardized interview and physical exam focused
on each subject’s ability to carry out activities of daily living. A more detailed description
of the assessment is included in Appendix A.
3.9 Sample Size Calculation
Sample size was calculated to detect a difference in median duration of BTH over
72 hours of continuous monitoring. Sample size was based on an adaptation of BOOSTII, an RCT that analyzed a similar outcome and population. Using this study, calculation
was made using sample size statistics in Power and Precision 4. For a given effect size
(population means of 0.440 vs 0.150), SD (0.310), sample sizes of 36 and 36, and alpha
(0.010, 2 tailed), power is 0.903. This means that 90% of studies would be expected to
yield a significant effect, rejecting the null hypothesis that the two-population means are
equal. In order to properly power our study to compare medians, we will add a 15%
correction (10 or more patients) to account for comparison of medians and correction for
losses to follow up. Therefore, in order to achieve an alpha of 0.050 and maintain power,
we estimate that we will need a sample size of 50 subjects in each study group, with a
final sample size of 100 patients. The sample size calculation will be included in
Appendix C.
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Table 4. Prevalence of BTH, ICH, or low CPP over 72-hour duration of trial
Variable
Subjects with BTH (SctO2 <50%), (n)
-Median Duration of BTH, (t)
Subjects with ICH (ICP ≥ 22), (n)
-Median duration of ICH, (t)
Subjects with reduced CPP (<60 mmHg)
- Median duration of reduced CPP, (t)

Measurement of Variable

Table 5. Glasgow Outcome Scale- Extended (GOS-E), evaluated at 6 months
Score
1= Dead
2= Vegetative State
3= Lower Severe Disability
4= Upper Severe Disability
5= Lower Moderate
Disability
6= Upper Moderate
Disability
7= Lower Good Recovery
8= Upper Good Recovery

Interpretation
Dead
Absence of awareness of self and environment
Needs full assistance in ADLs
Needs partial assistance in ADLs
Independent, but cannot resume work/school or all
previous social activities
Some disability exists, but can partly resume work or
previous activities
Minor physical or mental deficits that affect daily life
Full recovery or minor deficits that do not affect daily life

Table 6. Number of interventions required in each group throughout 72-hour period
Assignment Group and Type of
Intervention
Control
- Group B protocol
- Group D protocol
Intervention
- Group B protocol
- Group C protocol
- Group D protocol

Number of Interventions (total,
average per subject in group)
-

-

3.10 Analysis
Statistical analysis will occur with an intention-to-treat principle and be
performed using Mann-Whitney U for nonparametric variables for both our primary and
secondary outcomes. This statistical analysis is supported by previously reviewed studies
that have analyzed similar associations. Primary outcome will be to determine if
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treatment guided by cerebral oxygenation monitoring with NIRS in addition to ICP
monitoring can reduce the median duration of BTH burden over 72 hours as compared to
ICP monitoring alone. SctO2 values will be recorded continuously and logged every 5
minutes in order to obtain cerebral oxygenation data over a 72-hour span.
Our secondary outcome will be to determine functional outcome of each subject
in each of our groups at 6 months post initial injury utilizing the GOS-E on an 8-point
rating system. Each subject will receive a score by a trained researcher who will be
blinded to group allocation and interventions taken throughout the study. Additional
outcomes that will be evaluated include frequency and type of interventions by
assignment group and occurrence and type of SAE.
3.11 Timeline and Resources
Our study will be performed over a two-year time period beginning on July 1,
2020. This time frame includes recruitment and training of clinical staff, patient
enrollment and data collection, and outpatient follow-up. Anticipated timeline consists of:
recruitment and training of appropriate clinical staff across three locations (months 0-2);
phase 1 (and phase 2 dependent on timing of subject recruitment) of study protocol with
rolling recruitment until sample size is reached (months 2-18); completion of phase 2 of
study protocol (months 18-24). Phase 1 refers to the initial study protocol including
inpatient management and 72-hour monitoring and treatment period, while phase 2 refers
to the time period after 72 hours and the 6-month follow up visit. The last subject must be
enrolled no later than month 18 to ensure that each subject has a full 6 months before
follow up. Statistical analysis will occur immediately after the 6-month follow-up
appointments are completed following month 24 and are anticipated to take 1-2 months.
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Study protocol will be initiated immediately after each subject is hemodynamically stable
and consent is obtained from an LAR and will be complete after a total of 6 months and 3
days. Sufficient supply of monitors, ventilators and support equipment at each location
must be confirmed before any subject is enrolled. An outpatient exam site will be
confirmed in New Haven, CT for 6-month follow-up appointments provided by the Yale
New Haven Hospital Department of Neurology.
Study personnel at each site will include: one attending physician, two advanced
practice practitioners (physician assistants or nurse practitioners) and four nurses among
both trauma and intensive care units that will be recruited and trained in our study
protocol to ensure 24-hour coverage. Additionally, a research assistant for data collection,
a statistician and a GOS-E evaluator will be trained in pertinent aspects of our study.
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Chapter 4: Conclusion
4.1 Study Advantages
The major advantages of our proposed study lie primarily in its design,
methodology, and specific predetermined evidence-based treatment protocol.1,2 To date
there have been no large, prospective clinical trials examining noninvasive monitoring in
severe TBI, and no RCTs specifically analyzing cerebral NIRS as a monitoring technique
in adults within this population. Our proposed multicenter RCT aims to determine
whether cerebral oxygenation monitoring with NIRS can reduce the burden of BTH and
be incorporated into a standardized multimodal monitoring approach to guiding treatment
of severe TBI.
Most relevant studies on this matter are observational in nature, are subject to
physician biases,3-6 and contain a high prevalence of confounding factors. By matching
control and intervention groups among clinical sites and IMPACT prognostic scoring, our
study will drastically reduce the potential for confounding. Additionally, providing
proper training for clinical staff and implementing a fixed treatment protocol triggered by
specific, predetermined physiological variables will limit variability in treatment among
patients across multiple clinical locations. These measures will serve to increase our
study’s internal validity and reduce clinician biases.
Previous studies have been significantly limited by sample size, however with
utilization of three large, Level I trauma centers in CT over a 16-month period we will
ensure enrollment of an adequate sample size that will be generalizable to a larger
population. Our study has feasibly proposed a high quality, evidence-based protocol that
can potentially influence current guidelines and determine whether cerebral oxygenation
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monitoring with NIRS is a justified addition to the current guidelines for multimodal
monitoring of TBI.
4.2 Study Disadvantages
One major disadvantage of our study is the variability of injury. Although each
subject will be enrolled based on satisfaction of inclusion criteria, each mechanism of
injury, subsequent brain trauma, intracranial bleeding, and other sequelae of traumatic
injury are inherently different and cannot reasonably be controlled for based on our ideal
sample size and time restrictions. Importantly, significant scalp swelling and the presence
of intracranial hematomas can contaminate the NIRS signal and lead to inconsistent
measurements, and cannot be controlled for based on the nature of our population.7
Similar to a 2015 RCT by Hyttel-Sorensen, et al., a significant disadvantage of
our study design is that blinding of group allocation to trained clinical staff is
impossible.8 To execute the treatment protocol as designed, clinicians must know to treat
based on group allocation, and therefore cannot be blinded. However, since each protocol
is predetermined and physician bias is minimal, this should not have a significant effect
on our results. Additionally, in many cases the responsibility to maintain communication
with researchers and coordinate 6-month follow-up visits is dependent on each subject’s
LAR. This introduces burden to these representatives who are not directly participating in
the study and may potentially increase loss to follow-up or have a negative effect on
maintaining communication with each subject during the follow-up period.
4.3 Clinical and Public Health Significance
TBI is a leading cause of death and disability in the United States, accounting for
prolonged hospital admissions, financial stressors, and long-term reductions in functional
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status and quality of life. Current guidelines are focused on monitoring and treating
physiological variations in ICP and CPP in order to prevent secondary brain injury, but
there is a lack of level I prospective clinical evidence proving their efficacy. Cerebral
oxygenation monitoring with and without NIRS has also been examined in recent
literature as an addition to a multimodal monitoring strategy in managing these patients,
but research is inconclusive and techniques are imperfect. Considering the prevalence of
TBI and its potentially devastating effects, there is a clinical need for consensus on
monitoring techniques in management of these patients.
By proposing a prospective, multicenter RCT we aim to determine if cerebral
oxygenation with NIRS is a suitable technique to reliably monitor cerebral oxygenation
and reduce BTH in severe TBI patients. Its efficacy in this trial will potentially determine
if it is a safe, noninvasive alternative to invasive cerebral oxygenation monitoring, and if
it is of benefit in guiding management in our target population. Ultimately, our study will
help to clarify the current guidelines for monitoring and managing patients with severe
TBI and determine whether cerebral oxygenation monitoring with NIRS is suitable for
inclusion into a multimodal management approach for these patients.
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Appendices
Appendix A. Glasgow Outcome Scale- Extended (GOS-E)
Score
1= Dead
2= Vegetative State
3= Lower Severe Disability
4= Upper Severe Disability
5= Lower Moderate Disability
6= Upper Moderate Disability
7= Lower Good Recovery
8= Upper Good Recovery

Interpretation
Dead
Absence of awareness of self and environment
Needs full assistance in ADLs
Needs partial assistance in ADLs
Independent, but cannot resume work/school or all
previous social activities
Some disability exists, but can partly resume work or
previous activities
Minor physical or mental deficits that affect daily life
Full recovery or minor deficits that do not affect daily
life

Consisting of: (1) Detailed client interview (2) Collateral interviews (in person or
questionnaires) (3) Functional Testing (4) Synthesis of Data
Expanded Description of Categories:
8 levels are in the scale: Minimum score = 1, maximum score = 8
Level 1: Dead
Level 2: Vegetative State- condition of unawareness with only reflex responses but with
periods of spontaneous eye opening
Level 3 and 4: Lower and Upper Severe Disability – Patient who is dependent for daily
support for mental or physical disability, or usually a combination of both. If the patient
can be left alone for more than 8 hours at home, it is upper level of severe disability (4).
If patient cannot be left at home for more than 8 hours, it is considered lower level of
severe disability (3)
Level 5 and 6: Low and Moderate Disability- patients have some disability such as
aphasia, hemiparesis or epilepsy and/or deficits of memory or personality but are able to
care for themselves. They are independent at home but dependent outside. If they are able
to return to work with or without special arrangement, they are categorized as upper
moderate disability (6). If they are unable to return to work, they are categorized as lower
moderate disability (5).
Level 7 and 8: Lower and Upper Good Recovery- Resumption of normal life with the
capacity to work even if pre-injury status has not been achieved. Some patients have
minor neurological or psychological deficits. If these deficits are not disabling, then they
are categorized as upper good recovery (8). If these deficits are disabling, they are
categorized as lower good recovery (7).
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Appendix B. Sample HIC Consent Form
Created using 200 FR.7 HIC Consent For Participation in a Research Project Template
CONSENT FOR PARTICIPATION IN A RESEARCH PROJECT
200 FR. 7 (2016-1)
YALE UNIVERSITY SCHOOL OF MEDICINE – YALE-NEW HAVEN
HOSPITAL
HARTFORD HEALTHCARE- HARTFORD HOSPITAL
TRINITY HEALTHCARE- ST. FRANCIS HOSPITAL AND MEDICAL CENTER
Study Title: Cerebral Oxygenation Monitoring by Near-Infrared Spectroscopy in Severe
Traumatic Brain Injury
Principal Investigator: Emily J. Gilmore, MD
Co-Principal Investigator: Drew H. Zimmerman, PA-SII
Funding Source: The Brain Trauma Foundation
Invitation to Participate and Brief Description of the Project
You or the person you legally represent are invited to participate in a research study
called Cerebral Oxygenation Monitoring by Near Infrared Spectroscopy in Severe
Traumatic Brain Injury. This form is addressed to the person who will enroll in the study
but should also be reviewed by a legally authorized representative for consent if
applicable. This study is designed to determine the efficacy of a new monitoring
technique employed in patients with severe traumatic brain injury that will help guide
treatment and potentially improve functional outcomes. You have been invited to
participate because you have been diagnosed with a severe traumatic brain injury and
meet our study’s inclusion criteria. About 100 persons will be asked to participate in the
study over a 2-year time period.
In order to decide whether or not you wish to be a part of this research study you should
know enough about its risks and benefits to make an informed decision. This consent
form gives you detailed information about the research study, which a member of the
research team will discuss with you. This discussion should go over all aspects of this
research: its purpose, the procedures that will be performed, any risks of the procedures,
possible benefits and possible alternative treatments. Once you understand the study, you
will be asked if you wish to participate; if so, you will be asked to sign this form.
Description of Procedures
If you agree to participate in this study, you will be randomly assigned to one of
two treatment groups: (a) control group that will monitor you based on current guidelines,
and, (b) an experimental group that will monitor you based on current guidelines plus a
noninvasive measurement tool to assess your brain’s oxygen status. If placed in our
control group, you will be monitored and then treated with a predetermined protocol
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designed according to the current Guidelines for Management of Severe Traumatic Brain
Injury, 4th Edition, if warranted. In our experimental group, the same procedures will
apply, with addition of an extra monitoring strategy that will help guide a treatment
protocol with additional steps based on those values.
At the time of reading this consent, you have been brought to one of three
participating facilities included in this study (Yale-New Haven Hospital, Hartford
Hospital, or St. Francis Hospital) for evaluation of a traumatic head injury. Your injury
has been categorized as severe by our clinical staff and based on current guidelines you
meet clinical criteria for intracranial pressure monitoring.
Regardless of which group you are randomized to, you will undergo a procedure
that involves placing an intracranial pressure monitor, which is the standard of care for
managing patients with severe traumatic brain injury. We will sedate you with general
anesthesia and place a probe through a small hole into the skull. To insert the probe a
small cut is made in the scalp and a hole is drilled into the skull beneath the cut. The
probe is placed 1.5-2cm into the brain tissue and positioned close to, but not directly in,
the area injured. The probe is connected to an electronic measuring device that monitors
the brain pressure. You will then undergo a computed tomography (CT) scan to ensure
proper placement of the monitor. The cut will be closed with sutures or staples after the
trial and once it is no longer needed. You will not be aware of this procedure once under
sedation and will not experience any pain or physical sensation. You will be intubated
and placed on a ventilator before proceeding.
If you are randomly selected to participate in our experimental group, near
infrared spectroscopy detectors will be placed on your skull for additional monitoring of
your brain tissue oxygen levels. These detectors are stickers that are noninvasive and
require no surgical intervention. They will have multiple wires attached to them that will
transmit the information to our monitor for reading. If you are in our control group the
same monitors will be placed, but clinical staff will be instructed not to use information
from the near infrared spectroscopy detectors in determining your care. Throughout the
study, you and your family will not be aware of which group you have been selected to.
All monitors will be placed within 12 hours of your initial presentation to the
hospital, and once in place, information from them will be recorded for 72 hours. Over
that time period, a predetermined, evidence-based treatment protocol will be
implemented for any monitored value that is out of range. Treatment protocols are
dependent on which group you will be randomized to but will be consistent among all
participants in the study. After the 72-hour study period is complete, near infrared
spectroscopy monitors will be removed, and your treatment and subsequent hospital
course will be directed by individual hospital protocol.
After the 72-hour period is complete, investigators will contact you and/or your
LAR at scheduled intervals each month via e-email or phone call. During these periods of
communication, you will be asked to provide information on any location changes or
moves, hospital discharge or readmission, significant adverse events, or death. If you
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remain admitted or are readmitted to any of our participating hospitals, we will monitor
your electronic medical record for updates.
6 months after your hospital admission you will be asked to be present for a
follow up appointment with one of our researchers at our clinic in New Haven,
Connecticut. One week before this meeting, an investigator will contact you and review
logistics of travel and will reimburse you for any costs accrued while traveling to your
appointment. At this appointment, you will be asked a series of questions that will
indicate your functional ability to work and carry out activities of daily living, and then
will undergo a physical exam.
A description of this study is available on http://www.ClinicalTrials.gov, as
required by U.S. Law. This Web site will not include information that can identify you.
The purpose of this database is to allow everyone to see information on what studies are
being done, and what studies have been done. At most, the Web site will include a
summary of the results. You can search this Web site at any time.
Risks and Inconveniences
(1) Intracranial Pressure Monitoring: There are risks and complications with this
procedure. They include but are not limited to the following:
➢ Common risks and complications (more than 5%) include: minor pain,
bruising and/or infection from IV cannula site. This may require treatment
with antibiotics.
➢ Uncommon risks and complications (1-5%) include:
➢ Infection, requiring antibiotics and further treatment.
➢ Bleeding can occur and may require a return to the operating room. Bleeding
is more common if you have been taking blood-thinning drugs such as
Warfarin, Aspirin, Clopidogrel (Plavix) or Dipyridamole.
➢ Heart attack due to the strain on the heart.
➢ Stroke or stroke like complications may occur causing neurological deficits
such as weakness in the face, arms and legs. This could be temporary or
permanent.
➢ Fluid leakage from around the brain may occur through the wound after the
operation. This may require further surgery.
➢ Inadequate placement or malfunction of the probe and/or device. This may
require further surgery.
➢ Blood clot in the leg (DVT) causing pain and swelling. In rare cases part of
the clot may break off and go to the lungs.
➢ Rare risks and complications (less than 1%) include:
➢ Seizure which may require medication
➢ Injury to the brain, important nerves or blood vessels. This can lead to stroke
like complications.
➢ Death as a result of this procedure is very rare.
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(2) Near Infrared Spectroscopy Monitoring: There are minimal to no risks involved in
this monitoring technique. There is no need for injection of any medication, IV access or
surgical intervention. Areas of hair may need to be shaved in order to place the detectors
in proper position.
(3) Treatment Protocols: There are potential risks associated with each specific
intervention outlined in our treatment protocol. You will only receive treatment if
necessary, as outlined by our predetermined protocol.
➢ Medications given through IV cannula site may commonly result in minor pain,
bruising and/or infection from IV cannula site, which may require treatment with
antibiotics.
➢ Allergic reactions to medications are rare but possible, and allergies will be
reviewed with you and your clinical team before proceeding with any treatment.
➢ Known risks of blood transfusions include but are not limited to: infection or
irritation where the needle is placed, temporary reactions such as fever, chills, or
skin rashes. Other rare but more serious complications may occur such as allergic
reactions, heart failure due to fluid overload, acute pulmonary edema (fluid
leaking into the lungs), shock, or death. Transfusions of blood or blood products
involve a small risk of transmission of diseases such as Hepatitis B (~1 in
1,000,000), Hepatitis C (~1 in 1,200,000), and HIV/AIDS (~1 in 1,500,000).
There is also a small risk of bacterial infection when blood products are
transfused.
➢ Surgical intervention (placing an external ventricular drain (EVD), decompressive
craniectomy, or evacuation or newly formed brain bleeding) will only be taken if
absolutely necessary, and risks and benefits of these procedures will be discussed
and consented before proceeding on an individual basis.
Benefits
There are potential benefits resulting from the study including better recovery from injury
and faster return to baseline function, reduced length of hospital stay, reduced permanent
disability, and improved long term functional outcomes. This study may also provide
important clinical information that will help to clarify current guidelines for monitoring
and management of severe traumatic brain injury.
Economic Considerations
No compensation will be provided to participants or LARs in this study. One free parking
voucher will be provided for each LAR throughout the duration of the study, if
applicable. Participants will be reimbursed for any travel expenses pertaining to in person
follow up at their 6-month appointment.
Treatment Alternatives
If you choose not to participate in this study, treatment alternatives do exist. These
alternatives include the use of an ICP monitor and physician clinical judgment in
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treatment, however you will not have the opportunity to be managed based on cerebral
oxygen levels with a NIRS monitor. You may choose not to participate.
Confidentiality and Privacy
Any identifiable information that is obtained in connection with this study will remain
confidential and will be disclosed only with your permission or as required by U.S. or
state law. Examples of information that we are legally required to disclose include abuse
of a child or elderly person, or certain reportable diseases. Information will be kept
confidential by using only identification numbers on study forms, storing signed forms in
locked cabinets, and password protecting data stored on a computer. When the results of
the research are published or discussed in conferences, no information will be included
that would reveal your identity unless your specific permission for this activity is
obtained.
We understand that information about your health is personal, and we are committed to
protecting the privacy of that information. If you decide to be in this study, the researcher
will get information that identifies your personal health information. This may include
information that might directly identify you, such as his or her name and address,
telephone number, and email address, or mobile phone number. This information will be
de-identified at the earliest reasonable time after we receive it, meaning we will replace
your identifying information with a code that does not directly identify you. The principal
investigator will keep a link that identifies you and your coded information, and this link
will be kept secure and available only to the principal investigator or selected members of
the research team. Any information that can identify you will remain confidential.
Information will be kept confidential by using only identification numbers on study
forms, storing signed forms in locked cabinets, and password protecting data stored on a
computer. The research team will only give this coded information to others to carry out
this research study. The link to your personal information will be kept for 5 years, after
which time the link will be destroyed and the data will become anonymous. The data will
be kept in this anonymous form indefinitely.
All health care providers subject to HIPAA (Health Insurance Portability and
Accountability Act) are required to protect the privacy of your information. The research
staffs at the Yale School of Medicine, Hartford Hospital and St. Francis Hospital are
required to comply with HIPAA and to ensure the confidentiality of your information.
Representatives from the Yale Human Research Protection Program, the Yale Human
Investigation Committee (the committee that reviews, approves, and monitors research on
human subjects) may inspect study records during internal auditing procedures. However,
these individuals are required to keep all information confidential.
Voluntary Participation and Withdrawal
You are free to choose not to participate in this study. Your health care outside the study,
the payment for your health care, and your health care benefits will not be affected if you
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do not agree to participate. However, you will not be able to enroll in this research study
and will not receive study procedures as a study participant if you do not allow use of
your information as part of this study. You do not give up any of your legal rights by
signing this form.
Withdrawing from the Study
If you become a subject, you are free to stop and withdraw from this study at any time
during its course. To withdraw from the study, you or your LAR can call a member of the
research team at any time and tell them that you no longer want to take part. This will
cancel any future interventions or appointments.
The researchers may withdraw you from participating in the research if necessary. This
will only occur if continuation is considered unsafe or if there is a breach of
confidentiality or blinding. If you choose not to participate or if you withdraw it will not
harm your relationship with your own doctors or with the Yale School of Medicine, Yale
New-Haven Hospital, Hartford Hospital or St. Francis Hospital.
Questions
We have used some technical terms in this form. Please feel free to ask about anything
you don't understand and to consider this research and the permission form carefully – if
you feel is necessary – before you make a decision.
Authorization
My LAR or I have read (or someone has read to me) this form and have decided to
participate in the project described above. Its general purposes, the particulars of my
involvement and possible hazards and inconveniences have been explained to my
satisfaction. My signature also indicates that I have received a copy of this consent form.
You do not give up any of your legal rights by signing this form.
Name of Subject:_____________________________
Signature:___________________________________
Date:______________________________________
or
Name of Legally Authorized Representative:_____________________________
Signature:___________________________________
Date:______________________________________
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___________________________________________
Signature of Person Obtaining Consent

___________________
Date

If you have further questions about this project or if you have a research-related problem,
you may contact the Principal Investigator, Emily J. Gilmore, MD at (***) *******or the Co-Principal Investigator, Drew H. Zimmerman, PA-SII at (***) ***-****.
If you would like to talk with someone other than the researchers to discuss problems,
concerns, and questions, offer input, discuss situations in the event that a member of the
research team is not available, or if you have any questions concerning your rights as a
research subject, you may contact the Human Investigation Committee at (203) 7854688.
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Appendix C. Sample Size Calculation

Calculated using:
Power and Precision. Version 4.0. Biostat, Inc. Englewood, New Jersey.
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